Nephrology Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal; Nephrology and Infectious Diseases Research and Development Group, Instituto Nacional de Engenharia Biomédica-(I3S);
Faculdade de Medicina da Universidade do Porto, Department of Pharmacology and Therapeutics, Porto, Portugal;
Am J Physiol Renal Physiol. 2015 Jan 15;308(2):F84-91. doi: 10.1152/ajprenal.00274.2014. Epub 2014 Nov 19.
Renalase is a recently identified FAD/NADH-dependent amine oxidase mainly expressed in kidney that is secreted into blood and urine where it was suggested to metabolize catecholamines. The present study evaluated central and peripheral dopaminergic activities in the renalase knockout (KO) mouse model and examined the changes induced by recombinant renalase (RR) administration on plasma and urine catecholamine levels. Compared with wild-type (WT) mice, KO mice presented increased plasma levels of epinephrine (Epi), norepinephrine (NE), and dopamine (DA) that were accompanied by increases in the urinary excretion of Epi, NE, DA. In addition, the KO mice presented an increase in urinary DA-to-l-3,4-dihydroxyphenylalanine (l-DOPA) ratios without changes in renal tubular aromatic-l-amino acid decarboxylase (AADC) activity. By contrast, the in vivo administration of RR (1.5 mg/kg sc) to KO mice was accompanied by significant decreases in plasma levels of Epi, DA, and l-DOPA as well as in urinary excretion of Epi, DA, and DA-to-l-DOPA ratios notwithstanding the accompanied increase in renal AADC activity. In addition, the increase in renal DA output observed in renalase KO mice was accompanied by an increase in the expression of the L-type amino acid transporter like (LAT) 1 that is reversed by the administration of RR in these animals. These results suggest that the overexpression of LAT1 in the renal cortex of the renalase KO mice might contribute to the enhanced l-DOPA availability/uptake and consequently to the activation of the renal dopaminergic system in the presence of renalase deficiency.
肾酶是一种最近发现的 FAD/NADH 依赖性胺氧化酶,主要在肾脏中表达,分泌到血液和尿液中,据推测它可以代谢儿茶酚胺。本研究评估了肾酶敲除(KO)小鼠模型中的中枢和外周多巴胺能活性,并检查了重组肾酶(RR)给药对血浆和尿液儿茶酚胺水平的变化。与野生型(WT)小鼠相比,KO 小鼠的血浆肾上腺素(Epi)、去甲肾上腺素(NE)和多巴胺(DA)水平升高,同时 Epi、NE、DA 的尿排泄量增加。此外,KO 小鼠的尿 DA 与 l-3,4-二羟基苯丙氨酸(l-DOPA)的比值增加,而肾小管芳香族 l-氨基酸脱羧酶(AADC)活性没有变化。相反,RR(1.5 mg/kg sc)的体内给药可显著降低 KO 小鼠的血浆 Epi、DA 和 l-DOPA 水平,以及 Epi、DA 和 DA 与 l-DOPA 比值的尿排泄量,尽管伴随的肾 AADC 活性增加。此外,在肾酶 KO 小鼠中观察到的肾输出 DA 的增加伴随着 L 型氨基酸转运蛋白样(LAT)1 的表达增加,而 RR 在这些动物中的给药可逆转这种增加。这些结果表明,肾酶 KO 小鼠肾皮质中 LAT1 的过度表达可能有助于增强 l-DOPA 的可用性/摄取,从而在肾酶缺乏的情况下激活肾多巴胺能系统。